# Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

> **NCT05391750** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Emory University** · enrollment: 7 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Tocilizumab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05391750
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-19
- **Primary completion:** 2027-02-12
- **Final completion:** 2028-02-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05391750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05391750, "Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05391750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*